What is the price target for RXO stock?
26 analysts have analysed RXO and the average price target is 16.4 USD. This implies a price increase of 22.56% is expected in the next year compared to the current price of 13.38.
NYSE:RXO • US74982T1034
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RXO INC (RXO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-04 | Barclays | Maintains | Overweight -> Overweight |
| 2026-02-09 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-09 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-01-15 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-09 | TD Cowen | Maintains | Hold -> Hold |
| 2026-01-08 | Susquehanna | Maintains | Negative -> Negative |
| 2026-01-08 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-12-16 | Stifel | Maintains | Hold -> Hold |
| 2025-11-14 | Wolfe Research | Upgrade | Underperform -> Peer Perform |
| 2025-11-11 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-11-07 | UBS | Maintains | Neutral -> Neutral |
| 2025-11-07 | Susquehanna | Maintains | Negative -> Negative |
| 2025-11-07 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-07 | Truist Securities | Maintains | Buy -> Buy |
| 2025-10-10 | Stifel | Maintains | Hold -> Hold |
| 2025-10-09 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-10-08 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-10-03 | UBS | Maintains | Neutral -> Neutral |
| 2025-08-12 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-08 | UBS | Maintains | Neutral -> Neutral |
| 2025-07-08 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-07-07 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-21 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-05-16 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-05-08 | UBS | Maintains | Neutral -> Neutral |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.927B -18.12% | 4.55B 15.86% | 5.742B 26.20% | 5.787B 0.78% | 6.168B 6.58% | 6.658B 7.94% | 8.155B 22.48% | 9.174B 12.50% | 10.091B 10.00% | |
| EBITDA YoY % growth | 134M -56.21% | 117M -12.69% | 109M -6.84% | 111.69M 2.47% | 204.19M 82.82% | 295.08M 44.51% | 411.07M 39.31% | 497.93M 21.13% | 575.7M 15.62% | |
| EBIT YoY % growth | 67M -69.55% | 30M -55.22% | -7M -123.33% | 21.942M 413.46% | 111.97M 410.30% | 153.37M 36.97% | 275.73M 79.78% | 358.55M 30.04% | 432.28M 20.56% | |
| Operating Margin | 1.71% | 0.66% | -0.12% | 0.38% | 1.82% | 2.30% | 3.38% | 3.91% | 4.28% | |
| EPS YoY % growth | 0.30 -78.22% | 0.11 -63.33% | -0.05 -145.45% | 0.01 127.09% | 0.40 2,847.87% | 0.74 84.67% | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.09 -189.16% | -0.02 -139.97% | 0.06 462.27% | 0.09 233.80% | 0.04 146.57% | 0.14 952.81% | 0.17 196.39% | 0.20 110.29% |
| Revenue Q2Q % growth | 1.337B -6.70% | 1.405B -0.99% | 1.502B 5.70% | 1.59B 8.24% | 1.493B 11.67% | 1.584B 12.74% | 1.654B 10.12% | 1.744B 9.69% |
| EBITDA Q2Q % growth | 7.485M -65.98% | 24.234M -66.34% | 40.77M -54.70% | 53.833M -49.69% | 35.3M 371.61% | 63.378M 161.53% | 67.721M 66.10% | 73.478M 36.49% |
| EBIT Q2Q % growth | -16.635M -66.35% | 912.939K -90.87% | 18.405M 820.25% | 31.757M 452.86% | 17.675M 206.25% | 39.39M 4,214.64% | 45.45M 146.94% | 52.015M 63.79% |
All data in USD
26 analysts have analysed RXO and the average price target is 16.4 USD. This implies a price increase of 22.56% is expected in the next year compared to the current price of 13.38.
RXO INC (RXO) will report earnings on 2026-05-05.
The consensus EPS estimate for the next earnings of RXO INC (RXO) is -0.09 USD and the consensus revenue estimate is 1.34B USD.
The consensus rating for RXO INC (RXO) is 66.9231 / 100 . This indicates that analysts generally have a neutral outlook on the stock.